No Data
8 Years Survival With Complete Cure for a Patient With Advanced Liver Cancer Being Treated With Can-Fite's Namodenoson Drug
Can-Fite BioPharma Reports 8-Year Survival With Namodenoson in Liver Cancer Patient and Announces Phase III Study Enrollment
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
H.C. Wainwright Maintains Can-Fite BioPharma(CANF.US) With Buy Rating, Maintains Target Price $18
Promising Developments and Expanding Indications for Can-Fite BioPharma's Namodenoson: Analyst Recommends Buy
Express News | HC Wainwright & Co. Reiterates Buy on Can Fite Biofarma, Maintains $18 Price Target
No Data
No Data
Arrayfunction : As much as I would love their meds to pan out - liver cancer is a terrible way to go - it seems more like the company is circling the drain in my opinion. :-/
It is extremely unusual to report only a single participant in a clinical trial (even with the orphan drug and compassionate care destinations) as you can't draw any generalizable results for people at large with N=1. Sadly it reads more to me like the company doing their best to run PR before their cash flow gets completely eaten up by interest payments :-/
Northern Lights OP : Thank you for your insight/ opinion, appreciated.